The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The FDA aims to make a decision by April 8, 2026
The study met its primary endpoint and all 11 secondary efficacy endpoints
HYMPAVZI’s safety profile was generally favorable
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Subscribe To Our Newsletter & Stay Updated
